Vaxxinity, Inc. Class A Common Stock
VAXX
VAXX was delisted on the 8th of May, 2024.
58 hedge funds and large institutions have $8.73M invested in Vaxxinity, Inc. Class A Common Stock in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 8 closing their positions.
2% less funds holding
Funds holding: 59 → 58 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
20% less capital invested
Capital invested by funds: $10.9M → $8.73M (-$2.15M)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAS
Stelac Advisory Services
New York
|
+$102K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.5K |
| 3 |
Renaissance Technologies
New York
|
+$25.4K |
| 4 |
TI
Tidal Investments
Milwaukee,
Wisconsin
|
+$23.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$289K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$193K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$67.5K |
| 4 |
BlackRock
New York
|
-$65.9K |
| 5 |
Barclays
London,
United Kingdom
|
-$20.8K |
VAXX Hedge Fund Activity: Q1 2024 in Review
58 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Vaxxinity, Inc. Class A Common Stock (VAXX) for Q1 2024, worth a combined $8.73M — down 20% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VAXX and 7 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 11 added.
The largest buyer was Stelac Advisory Services, opening a new position worth an estimated $102K. The largest seller was Morgan Stanley, cutting an estimated $289K.
- 58 institutional investors held Vaxxinity, Inc. Class A Common Stock (VAXX) as of Q1 2024, down from 59 in Q4 2023.
- Funds reported $8.73M of Vaxxinity, Inc. Class A Common Stock stock for Q1 2024, down 20% quarter-over-quarter.
- 7 funds opened new Vaxxinity, Inc. Class A Common Stock positions in Q1 2024 and 8 closed out, a net change of -1 holder.
- The largest Vaxxinity, Inc. Class A Common Stock buyer in Q1 2024 was Stelac Advisory Services, an estimated $102K added.
- The largest Vaxxinity, Inc. Class A Common Stock seller in Q1 2024 was Morgan Stanley, an estimated $289K sold.
Based on aggregated 13F filings for Q1 2024.